Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call on May 5, 2022, at 8:00 a.m. ET to discuss its Q1 2022 financial results and business highlights. Investors can access the live webcast on Agios's website, with a replay available two hours post-event. The company focuses on genetically defined diseases and has developed a first-in-class pyruvate kinase activator for PK deficiency. Agios is advancing a clinical pipeline targeting alpha- and beta-thalassemia, sickle cell disease, and more.
- Agios has developed a first-in-class pyruvate kinase activator for adults with PK deficiency.
- The company is advancing a robust clinical pipeline with investigational therapies for various genetic diseases.
- None.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday, May 5, 2022, at 8:00 a.m. ET to report its first quarter 2022 financial results and other business highlights.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 5738266. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com
Contacts Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com
Media:
Jessica Rennekamp, 857-209-3286
Director, Corporate Communications
Jessica.Rennekamp@agios.com
Source: Agios Pharmaceuticals, Inc.
FAQ
When will Agios Pharmaceuticals report its Q1 2022 financial results?
How can I access Agios Pharmaceuticals' Q1 2022 financial results conference call?
What is the focus area of Agios Pharmaceuticals?
